References
- GOLD (Global initiative for chronic Obstructive Lung Disease)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda (MD)GOLD2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdfAccessed May 15, 2015
- World Health OrganizationChronic respiratory diseases: burden of COPD Available from: http://www.who.int/respiratory/copd/burden/enAccessed May 15, 2015
- KimCYooKHRheeCKHealth care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in KoreaInt J Tuberc Lung Dis20141873774324903947
- TanWCNgTPCOPD in Asia: where East meets WestChest200813351752718252918
- ZhongNWangCYaoWPrevalence of chronic obstructive pulmonary disease in China: a large, population-based surveyAm J Respir Crit Care Med200717675376017575095
- DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med20131071538154623830094
- CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 μg in COPD: a randomized, controlled studyChest201414598199124385182
- DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med2014247248624835833
- MalerbaMMorjariaJBRadaeliADifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD - role of umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2014968769525061288
- DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
- CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J20042393294615219010
- HankinsonJLKawutSMShaharESmithLJStukovskyKHBarrRGPerformance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung studyChest201013713814519741060
- HankinsonJLOdencrantzJRFedanKBSpirometric reference values from a sample of the general U.S. populationAm J Respir Crit Care Med19991591791879872837
- JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD20052757917136966
- Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med20141081752176025458157
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
- DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med20131071558156723867808
- ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
- ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via accuhaler in Chinese patients with COPDChest20071321756176317951625